Overexpression of TGN38/41 leads to mislocalisation of γ-adaptin  by Reaves, Barbara & Banting, George
FEBS Letters 351 (1994) 448-456 
FEBS 14426 
Overexpression of TGN38/41 leads to mislocalisation of y-adaptin 
Barbara Reaves**, George Banting* 
Department of Biochemistry, School f Medical Sciences, University of Bristol, University Walk, Bristol BS81TD, UK 
Received 15 June 1994; revised version received 20 July 1994 
Abstract 
TGN38 and TGN41 are isoforms f a monotopic integral membrane protein which recycles between the trans Golgi network (TGN) and the cell 
surface, but which, at steady state, is predominantly located in the TGN. Full-length and truncated versions of ratTGN38/41 have been xpressed 
in monkey (COS) and human (Heb7a) cells und r the control of the heavy metal inducible Metallothionein IIA promoter. This has allowed the 
regulated expression fTGN38/41 protein constructs to different l v ls in the transfected c lls. These studies show that (i) controlled overexpression 
of TGN38/41 results in mislocalisation to parts of the endocytic pathway, (ii) a truncated version of TGN38/41, lacking the cytoplasmic domain, 
remains in the TGN, and (iii) there is a direct or indirect interaction between the cytoplasmic domain of TGN38/41 and y-adaptin. 
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1. Introduction 
The trans-Golgi network (TGN) acts as a sorting cen- 
tre for proteins destined for the plasma membrane, lyso- 
somes and regulated secretory granules and has been 
shown to be an organelle independent of the Golgi stack 
[1,2]. TGN38 and TGN41 are two isoforms of a type I 
integral membrane protein which has been localized to 
this compartment [3,4]. Although TGN38/41 is concen- 
trated in the TGN it also recycles between the TGN and 
the plasma membrane [5,6]. Localization signals for the 
TGN have recently been investigated in four separate 
studies [7-10] using both chimeric proteins and deletion 
or point mutations of TGN38/41. A role for the cytoplas- 
mic domain in either targetting or retention was impli- 
cated by transient ransfection studies [3] in which over- 
expression of TGN38 or deletion of the cytoplasmic 
domain resulted in mislocalization to the cell surface. 
Transient transfectants expressing both chimeric con- 
structs using the lumenal domain of the LDL receptor 
attached to the cytoplasmic tail of TGN38 as well as 
deletion and point mutations in the wild type TGN38 
sequence [8] have been used to probe the exact sequences 
necessary for TGN localization. In addition, stable cell 
lines expressing the lumenal and transmembrane do- 
mains of either the Tac antigen [7] or glycophorin A [9] 
attached to the cytoplasmic domain of TGN38 gave sim- 
ilar results. All three studies identified the sequence 
*Corresponding author. Fax: (44) 272 288274. 
YQRL, in particular the tyrosine and leucine residues, 
in the cytoplasmic tail as being important for targetting 
to the TGN and retreival from the plasma membrane. 
Wong and Hong [9] also identified a serine residue close 
to the tyrosine (SDYQRL) as an additional requirement 
for TGN localization, whilst Humphrey et al. found that 
mutation of arginine to glutamic acid in the YQRL se- 
quence resulted in efficient internalization, but not TGN 
localization. This suggests that the specificity of localiza- 
tion signals may be contained within individual members 
of the generic tyrosine-containing internalization motif. 
This is discussed elsewhere [11,12]. Experiments using 
other chimeric proteins have recently shown that the 
transmembrane domain of TGN38/41 plays a role in 
retention within the TGN [10]. 
An important consideration i  analyzing the effect of 
mutations and deletions on subcellular localization s the 
level of expression of a transfected protein. Overexpres- 
sion of wild-type and chimeric proteins containing the 
proposed localization signal for TGN38 resulted in mis- 
localization to the plasma membrane and vesicles scat- 
tered throughout he cytoplasm [3,7,9] suggesting that 
the mechanism for retention and/or targetting is satura- 
ble. In order to investigate his further we have isolated 
stably transfected cell lines incorporating an inducible 
expression system whereby the expression of TGN38/41 
can be increased incrementally. We have used this system 
to monitor the subcellular distribution of both wild type 
TGN38/41 and TGN38/41 lacking a cytoplasmic do- 
main. 
**Present address: Dept. of Clinical Biochemistry, Addenbrookes Hos- 
pital, University of Cambridge, Cambridge, CB2 2QR, UK. 
Abbreviations: FACS, fluorescence activated cell sorter; BFA, Brefeldin 
A; FITC, fluorescein isothiocyanate; MTOC, Microtubule Organising 
Centre; TRITC, Texas red isothiocyanate; TGN, trans-Golgi network 
2. Materials and methods 
2.1. Reagents 
Cell culture media (DMEM), foetal calf serum and antibiotics were 
from Gibco Life Technologies, Inc. (Paisley, Scotland). Hygromycin B,
Boehringer Mannheim (Lewes, East Sussex, UK) was used at a final 
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concentration of 200 gg/ml. Brefeldin A from Epicentre Technologies 
(Madison, WI) was used as previously described [1]. FITC-transferrin 
was from Molecular Probes, Inc. (Eugene, OR) and was used at a final 
concentration of 20 pg/ml, nsI-Protein G was prepared with 0.75 mCi 
of =251 (NEN, UK) and 15 pg of Protein G (Pharmacia, UK) using the 
Iodogen method of labelling [13]. ~106 epm/ml were used per im- 
munoblot. 
2.2. Antibodies 
The rabbit anti-rat TGN38 polyclonal antiserum used for the inter- 
nalisation and double-labelling experiments has been previously de- 
scribed [3] The polyclonal antibody used in immunoblotting was raised 
to a fl-galactosidase-TGN41 fusion protein [14]. For the majority of the 
immunofluorescence experiments a monoclonal ntibody raised to the 
13 amino-terminal mino acids of TGN38 was used [15]. The anti-y- 
adaptin antibody mAb 100/3 [16] was a kind gift of E. Ungewickell. 
FITC-, TRITC- and phycoerytherin-labelled goat anti.mouse and goat 
anti-rabbit antibodies were from Sigma Chemical Co. (Poole, Dorset, 
UK). 
2.3. Expression constructs 
Unless otherwise stated, all DNA manipulation procedures were 
performed as described elsewhere [17]. The pMEP4-TGN38/41 con- 
structs were made by inserting the full-length cDNA for either TGN38 
[3] or TGN41 [4] into the BamHI site of pMEP4 (Invitrogen, CA). 
pMEP4 contains a multiple cloning site downstream of the human 
metallothionein IIA promoter. This promoter can be induced by heavy 
metals. The vector also carries the hygromycin resistance gene allowing 
selection of transfected eukaryotic ceils in medium supplemented with 
hygromycin B. The TGN38/41 tail deletion was constructed by PCR 
using a mutagenic 3' oligonucleotide, GATCGGATCCAAAAG- 
CAATTCACTTTCGTTTG which substitutes a stop codon for the 
isoleucine 3residues away from the end of the transmembrane domain 
(i.e. KRKI to KRKstop) and a 5' oligonucleotide ATCGGATCCA- 
GACTACAGGATGCAGTTCCTGG corresponding to the first 24 
bases of the TGN38/41 sequence [3]. Sequences of all constructs were 
verified by double-stranded DNA sequencing using a Sequenase Ver- 
sion 2.0 kit (United States Biochemicals) and [3SS]dATP (NEN, UK) 
following the manufacturer's protocol. Proteins expressed in pMEP4 
are represented diagramatically in Fig. 1. 
2.4. Cell culture and transfection 
COS (African Green Monkey Kidney) [18] and Heb7a (human, Hela 
derivative)[19] cells were grown in DMEM plus 10% FCS with 100 u/ml 
penicillin and 100pg/ml streptomycin. Cells were grown to ~ 80% contiu- 
ency, harvested by scraping using a cell lifter (Costar) scraped, and 
washed in ice cold PBS. After pelleting, 5-10 x 106 cells were resus- 
pended in 0.8 ml HEBS buffer (20 mM HEPES, pH 7.05, 137 mM 
NaCI, 5 mM KC1, 0.7 mM Na2HPO4, 250 mM sucrose) containing 20 
pg of plasmid and transferred to a 0.4 cm electroporation cuvette 
(Bio-Rad). Cells were then electroporated at 0.22 kV, 960/IF using a 
BioRad Gene Pulser apparatus [20]. After a 10 min incubation at room 
temperature, cells were plated in 140 x 25 cm tissue culture dishes. 
Selection with hygromycin B was started 48 h post-plating and after ~2-3 
weeks colonies were isolated and transferred to multi-well plates for 
expansion. Positive clones were identified by immunofluorescence as 
described below. 
WILD TYPE TGN41 
2.5. FACS analysis 
Transfected cells were grown to confluency in T25 tissue culture 
flasks, treated with varying doses of CdC12 and then processed for 
FACS analysis as follows. Ceils were removed from the flasks using 
Hank's Balanced Salt Solution (Gibco Life Technologies, Inc., Paisley, 
Scotland) containing 10 mM EDTA (Sigma Chemical Co., Poole, 
Dorset, UK). After several washes in the same medium, cells were 
pre-incubated for 20 min on ice in PBS/0.2% BSA/0.02% sodium azide 
and then for a further hour with a 1:250 dilution of a rabbit anti-rat 
TGN38/41 [3] which recognises the N-terminal portion of the protein 
[14]. After 3 washes in PBS/BSAJazide the cells were incubated for 45 
min on ice with a 1:40 dilution of goat anti-rabbit IgG-phycoerytherin 
diluted in 20% normal goat serum in PBS/azide. Immediately prior to 
FACS analysis, cells were washed with and resuspended in 0.2 ml of 
calcium/magnesium-free PBS.Analysis was carried out at Bristol Uni- 
versity Veterinary School on an EPICS CS fluorescence activated cell 
sorter (Coulter Electronics, Ltd., Luton, Herts. UK) using an argon 
laser at 488 nm collecting log red fluorescence and linear forward light 
scatter. 
2.6. Immunofluorescence and confocal microscopy 
Immunofluorescence microscopy was carded out as previously de- 
scribed [1]. 
2.7. Protein analysis 
Untransfected COS cells and cells stably transfected with pMEP- 
TGN41 were grown to confluency and then treated with 0-20 pM 
CdCl2 for 18-20 h prior to processing. Cells were harvested by scraping 
using a cell lifter (Costar), pelleted and washed in ice cold PBS prior 
to lysis in CLB (10 mM Tris, pH 7.4, 0.15 M NaCl, 1% NP-40, l mM 
EDTA, l0 mM PMSF, 2 mM benzamidine, 50 Kallikrein units/ml 
aprotinin, 0.05 mg/ml leupeptin, 0.05 mg/ml antipain) for 15 min on ice. 
Nuclear and non-solubilised material was removed by centrifugation 
at 4"C and 10,000 x g. Protein determinations were carried out accord- 
ing to the method of Bradford [21] and I00 pg of protein loaded per 
lane of an 8% SDS PAGE gel [22] and electrophoresis carried out until 
the 69 x 103 Mr marker eached the bottom of the gel. Following dec- 
trophoresis and electro-transfer, performed as previously described [3] 
the nitrocellulose was incubated with a rabbit polyclonai anti-TGN38/ 
41 antibody binding of which was detected by incubation with '25I- 
labelled Protein G followed by autoradiography for18 h. Densitometry 
was carded out after an overnight exposure on a Molecular Dynamics 
Phosphoimager. Total =251 is expressed relative o c.p.m, detected at the 
same position of a lane containing only loading buffer. 
3. R ~  
3.1. Effects o f  increasing expression on TGN38141 
localisation 
I t  has been demonst ra ted  prev ious ly  that  overexpres-  
s ion o f  TGN38/41  leads to its mis loca l isat ion to the cell 
surface [3]. In  o rder  to al leviate the prob lem o f  overex-  
press ion in interpret ing results o f  mutagenes is  experi -  
~ ~ ~ - N K R  KIIAFALEGKR SKVTR RP KAS DYQR LNQNQS FDFDFVCKNLVLPADLFPNQEK 
TGN38/41 A TAIL 
Fig. 1. Representations of the proteins encoded by cDNA sequences cloned into the eukaryotic expression vector pMEP4. Lumenal domains of 
proteins are indicated by a hatched box and transmembrane domains by a solid box. The entire amino acid sequence of each cytoplasmic domain 
is presented. 
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Fig. 2. Immunofluorescence a alysis of TGN41 induction byvarying doses of CdCl 2. COS41-1 cells were treated for20 h with CdCl 2 prior to methanol 
fixation and processing for immunofluorescence microscopy using a species-specific anti-rat TGN38/41 polyclonal antibody as described insection 
2. (A = 0, B = 1.25, C = 2.5, D = 5.0, E = 10.0, F = 20.0pM CdCI2). 
ments designed to identify TGN localisation signals, we 
sought to establish stable inducible cell lines expressing 
rat TGN38 or rat TGN41, Polyclonal and monoclonal 
antibodies are available which recognise rat but not 
human or monkey TGN38/41 [15,21]. Monkey (COS) 
and human (Heb7a) cells were transfected by electropo- 
ration with pMEP4 constructs encoding either rat 
TGN38 or TGN41. In each case the relevant cDNA was 
cloned downstream of the human metallothionein I IA 
promoter to allow inducible expression by addition of 
CdC12 to the tissue culture medium. Stable cell lines were 
isolated as described in section 2. Clonal COS cell lines 
expressing TGN41 (as assayed by immunofluorescence 
analysis using anti TGN38/41 antibodies) were isolated. 
All showed a similar pattern in the immunofluorescence 
screen and one, COS41-1 was chosen for further study. 
Cells were treated with 0-20 gM CdC12 for 20 h prior 
to processing for immunofluorescence analysis. A mono- 
clonal antibody raised to the N-terminal 13 amino acids 
of rat TGN38/41 fails to recognise the endogenous sim- 
ian protein thus allowing detection of rat proteins en- 
coded by the transgene. There was some TGN41 expres- 
sion without any added CdC12 (Fig. 2A), however, 
increasing doses resulted in a corresponding increase in 
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intensity of TGN41 staining (Fig. 2B-F). At low doses, 
1.25 and 2.5/zM CdCI2, the pattern of staining resembles 
that seen for the endogenous protein in NRK cells [1] 
(Fig. 2B,C), i.e. a tight perinuclear concentration. As is 
the case for the endogenous rat protein, the transfected 
cells varied in terms of the reticular versus vesicular na- 
ture of this staining. At 5/IM CdC12 the pattern is simi- 
lar, however, the intensity of staining is increased (Fig. 
2D). Starting at 10/tM CdC12 and becoming more pro- 
nounced at 20/tM CdC12, not only does the intensity 
increase but the pattern of staining no longer esembles 
the tight pattern of staining seen at lower doses (Fig. 
2E,F). A number of different morphologies are present, 
the most common being a disruption of the concentrated 
staining around the nucleus accompanied by large and 
small vesicles cattered throughout the cytoplasm and in 
some cells the appearance ofTGN41 at the cell surface. 
In some cases a large reticular network extending 
throughout the cell can also be seen (data not shown). 
20/zM CdC12 has no effect on TGN morphology or the 
intracellular distribution of either at TGN38/41 in NRK 
cells or of the simian TGN38/41 in COS ceils (data not 
shown). These criteria were assayed in COS cells using 
an antibody which recognises the endogenous protein in 
these cells [14]. This dose of CdCI2 has previously been 
shown to have no detectable toxic effects in cells in tissue 
culture during the time course of the experiment de- 
scribed [23]. 
To investigate he relationship between the pattern of 
staining and actual protein level of TGN41, COS41-1 
cells were treated as above with 0-20/zM CdC12, and 100 
/tg of protein from either a post-nuclear supernatant or
a total membrane fraction was subjected to SDS-PAGE 
and then immunoblotted using anti-rat TGN38/41 as 
primary antibody. The results are presented inFig. 3. An 
increase in the level of expression of TGN41 protein is 
seen with increasing dose of CdC12 There was no detect- 
able TGN41 expression i untransfected COS cells (data 
not shown). Quantitation by densitometry evealed a 
10-fold increase in TGN41 expression in cells treated 
with 20/zM CdCI2 compared to untreated cells.Thus, the 
tendency for apparent mislocalisation of TGN41 corre- 
lates with a 10-fold increase in protein expression. Simi- 
lar results were obtained with (i) other clonal permanent 
COS transfectants expressing TGN41 (ii) permanent 
COS transfectants expressing TGN38 and (iii) clonal 
permanent Heb7a transfectants expressing either 
TGN38 or TGN41. 
3.2. Localisation of TGN38141 at varying levels of
expression 
3.2.1. Colocalisation with 7/-adaptin 
7/-adaptin is a coat protein which specifically associ- 
ates with TGN membranes [16,24]. Double-labelling im- 
munofluorescence experiments were performed using a 
.{ |ill t . . . . .  
1 2 3 4 5 6 
p,g CdC12 added 0.00 1.25 2.50 5.00 10.0 20.0 
cpm in * band 37181 75370 107201 209077 265962 396625 
fold induction 1.00 2.03 2.88 5.62 7.15 10.67 
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Fig. 3. Immunoblotting analysis of CdC12 induced TGN41 expression. 
Confluent COS41-1 cells were treated with CdC12 for 20 h prior to lysis 
and preparation of post-nuclear supernatant. 100/zg of total protein per 
lane was separated on an 8% SDS-PAGE gel and immunoblotted using 
rabbit anti-rat TGN38/41 and 1251 Protein G. The presence of TGN41 
protein was visualised by autoradiography. Lane 1 = 0, lane 2 = 1.25, 
lane 3 = 2.5, lane 4 = 5.0, lane 5 = 10.0 and lane 6 = 20/.tM CdClz The 
electrophoretic mobility of molecular weight standards (Mr × 10 -3) is 
indicated on the right. Quantitation of the immunoblot was performed 
on a Molecular Dynamics Phosphorimager and the results are repre- 
sented as a fold-increase over non-induced ceils. 
species-specific polyclonal anti-rat TGN38/41 antibody 
and a monoclonal antibody to human 7/-adaptin [16] 
which also recognises imian 7/-adaptin. This was in 
order to confirm that rat TGN41 expressed in trans- 
fected COS cells co-localised with the endogenous 7/- 
adaptin and was therefore correctly localised to the 
TGN. COS41-1 cells were treated with either 2.5/tM or 
20/.tM CdCI 2 and processed for immunofluorescence as 
described. At low doses of cadmium TGN41 and 7/- 
adaptin colocalise to the same perinuclear location (Fig. 
4A,B). It is of note that at higher doses of cadmium, 
when TGN41 expression is elevated and the protein can 
be detected in diverse vesicles as opposed to the original 
perinuclear location, the pattern of anti-y-adaptin stain- 
ing is altered in a similar manner (Fig. 4C,D). These data 
could be interpreted to suggest hat overexpression f
TGN41 leads to an expansion of the TGN rather than 
its mislocalisation to other compartments. This would 
imply that TGN41 plays a pivotal role in defining the 
TGN as being the TGN. Alternatively they might be 
interpreted toshow that there is a direct or indirect inter- 
action between TGN41 and y-adaptin, so that when 
TGN41 is present in significant amounts in extra-TGN 
structures those structures become coated with 7/- 
adaptin. The following experiments were performed in 
order to help address these points. 
3.2.2. Brefeldin A treatment 
Brefeldin A (BFA) has been shown to cause a collapse 
of the TGN around the MTOC [1,5]. This is in contrast 
to its actions on the rest of the Golgi stack which redis- 
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Fig. 4. Immunofluorescent localisation of recombinant TGN41 to the TGN in COS41-1 cells. (A-D) Colocalisation with y-adaptin. COS41-1 cells 
were treated with either 1.25(A and B) or 20/tM CdCI2 (C and D) for 20 h prior to processing for immunofluorescence. Methanol fixed cells were 
incubated with a species-specific anti-rat TGN38/41 polyclonal antibody (A and C) followed by anti-rabbit IgG-TRITC or a mouse anti-human 
y-adaptin monoclonal antibody followed by anti-mouse IgG-FITC (B and D). (E and F) BFA treatment ofCOS41-1 cells. COS41-1 cells were treated 
with 1.25 /tM CdClz (E) or 20/IM CdC12 (F) and then incubated in the presence of 5/lg/ml Brefeldin A for 3 h prior to processing for 
immunofluorescence with a rabbit anti-rat TGN38/41 antibody followed by anti-rabbitIgG-TRITC. 
tributes into the ER [25]. BFA therefore provides a valu- 
able tool for identifying the TGN.  After inducing 
TGN41 expression in COS41-1 cells with either 2.5 or 
20 / tM CdCI2, 5 ktg/ml BFA was added to the medium 
and cells incubated for a further 3 h at 37°C. Im- 
munofluorescence analysis of  cells exposed to low doses 
of  cadmium revealed the typical tight 'BFA dot'  (Fig. 
4E) observed for endogenous TGN38/41 in NRK cells 
[1]. This indicated that, at his level of  expression, rat 
TGN41 is appropriately localised in transfected COS 
cells. However, at higher doses of  cadmium, in addition 
to the concentration of  staining at the MTOC,  vesicles 
are also seen dispersed throughout he cytoplasm (Fig. 
4F). These resemble those observed in highly induced, 
non-BFA treated cells (compare Figs. 2F and 4F). Thus, 
some component of  the redistributed TGN41 is not sus- 
ceptible to the action of  BFA on the TGN suggesting 
that its overexpression leads to accumulation in extra- 
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Fig. 5. Colocalisation of endocytosed FITC-transferrin and recombi- 
nant TGN41 in COS41-1 cells expressing elevated levels of the protein. 
COS41-1 cells were t ated with 20 pM CdCI: prior to incubation i  
20 mg/ml FITC-labelled transferrin for 2 h prior to fixation and proc- 
essing for immunofluorescence analysis using a mouse monoclonal 
anti-rat TGN38/41 antibody and goat anti-mouse TRITC. Internalised 
transferrin is visualised in panel A, TGN41 in panel B. 
TGN structures, not  just in highly vesiculated forms of  
the TGN.  
3.3. Characterisation of  the TGN41-containing vesicles in 
transfected COS cells 
Are these structures early endosomes? To determine 
whether there is any local isation of  overexpressed 
TGN41 to early endosomes, COS41-1 cells were treated 
with 20 /zM CdCI2. 20/ tg /ml  F ITC- label led transferr in 
was added to the medium and cells incubated for 2 h 
pr ior  to f ixation and processing for immunofluorescence 
analysis using the mouse ant i -rat  TGN38/41 ant ibody 
and goat ant i -mouse TR ITC.  The major i ty  of  vesicles 
which are detected with anti -TGN38/41 ant ibody (Fig. 
5A) also stain with F ITC-t ransferr in  (Fig. 5B) suggesting 
the per ipheral  structures containing TGN41 are predom- 
inantly early endosomes. 
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Fig. 6. FACS analysis of surface expression of full-length TGN41 in cos  cells (COS41-1) and truncated TGN38/41 (lacking a cytoplasmic domain) 
in Heb7a cells (HebdTail-3) using a monoclonal ntibody to an amino-terminal epitope on the lumenal domain of TGN38/41. COS41-1 cells treated 
with 0 (A), 2 (B) or 20 (C)/.tM CdCI2 and HebATail-3 cells treated with 0 (D) or 20 (E) pM CdC12 were processed as described in section 2. Log 
red fluorescence is plotted on the x-axis versus (forward light scatter) number of cells on the y-axis. 
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Fig. 7. Immunofluorescent localisation of truncated TGN38/41 (lacking a cytoplasmic domain) in Heb7a cells (HebATail-3). (A and B) Increased 
levels of CdCI 2 elevate xpression of the truncated protein. HebATail-3 cells were treated with 2.0 (A) or 20 (B)/aM CdCI z prior to methanol fixation 
and processing for immunofluorescence analysis using a rabbit anti-rat TGN38/41 antibody. (C and D) Co-localisation with y-adaptin. Cells were 
treated with 10/aM CdCI z prior to fixation and incubation with a rabbit anti-rat TGN38/41 antibody followed by goat anti-rabbit TRITC (C) and 
a mouse anti-human y-adaptin antibody followed by goat anti-mouse FITC (D). 
3.4. Cell surface expression of TGN41 
Is there an increased expression of TGN41 at the cell 
surface in cells which are expressing elevated levels of the 
protein? COS41 1 cells were treated with 0, 2.0 or 20/IM 
CdC12 and processed for FACS analysis as described in 
section 2. As can be seen in Fig. 6A-C there was no 
significant difference between the three samples. This is 
consistent with results from immunofluorescence analy- 
sis of non-permeabilised cells (data not shown). These 
data suggest that TGN41 is not accumulating at the cell 
surface at the levels of expression which cause its intra- 
cellular mislocalisation. The saturable sorting machinery 
responsible for accurate TGN localisation may therefore 
only come into play after internalisation has occurred. 
Similar results were obtained with Heb7A constructs ex- 
pressing TGN41 (data not shown). 
3.5. Cytoplasmic domain deletion mutants of TGN38/41 
localise to both the cell surface and TGN and do not 
lead to mislocalisation of T-adaptin 
Having characterised the expression of full-length 
TGN38 and 41 in permanently transfected cells, and 
ascertained levels of expression which result in appropri- 
ate and inappropriate localisation of the protein, we 
chose to address the question of the role played by the 
cytoplasmic domain of the protein in its localisation to 
the TGN. A number of reports, using various constructs 
and expression systems, have demonstrated that deletion 
of the cytoplasmic domain of TGN38/41 results in its 
expression at the cell surface [3,7,8,9]. The original de- 
scription [3] was of transiently transfected cells which 
expressed recombinant protein at very high levels. This 
system has been modified to give slightly lower levels of 
expression [8]. The other two studies [7,9] used the lume- 
nal and transmembrane domains of other cell surface 
reporter proteins attached to the cytoplasmic domain of 
TGN38/41. In all the above studies, levels of transgene 
expression were unregulated, and significantly higher 
than those for endogenous TGN38141 in rat cells. Since 
our studies with full-length rat TGN41 expressed in COS 
cells had shown that over-expression f the protein led 
to its mislocalisation, we chose to ask whether the level 
of protein expression affected the localisation of a trun- 
cated TGN38/41 molecule lacking the majority of the 
cytoplasmic domain. To address this question Heb7a 
cells were transfected with a pMEP4-TGN38141 cyto- 
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plasmic domain deletion construct (TGN38/41 A TAIL 
in Fig. 1) and stably expressing cell lines established. One 
cell line designated HebATail-3 was chosen for further 
study, however, the same results were obtained with 
other cell lines. HebATail-3 cells were treated with 2.5 or 
20 /tM CdCI 2 and processed for immunofluorescence 
microscopy using a monoclonal ntibody to the N-termi- 
nus of TGN38/41. Cell surface staining was apparent at 
low doses of CdC12 (Fig. 7A). The intensity of this stain- 
ing increased with increasing expression levels obtained 
by treatment with higher doses of CdC12 (Fig. 7A,B). 
Interestingly, in addition to the cell surface staining a 
concentration f staining in the perinuclear area was also 
visualised at both high and low levels of expression (Fig. 
7A,B). The increase in level of expression at the cell 
surface was confirmed by FACS analysis (Fig. 6D,E) of 
HebATail-3 cells. A 10-fold increase in CdCI2 leading to 
a 10-fold increase in cell surface xpression. 
In order to determine whether the perinuclear staining 
corresponded to a population of TGN41 localised to the 
TGN, cells were incubated in 2.5/IM CdCI2, prior to 
processing for double-label immunofluorescence analy- 
sis using the monoclonal nti-7-adaptin antibody and a 
species-specific anti-rat TGN38/41 polyclonal antibody. 
The perinuclear concentration of TGN38/41 staining 
colocalised with the 7-adaptin staining (Fig. 7C,D) sug- 
gesting that some of the mutant protein was located in 
the TGN. It is noticeable that there is no apparent mislo- 
calisation of 7-adaptin in cells overexpressing d TAIL 
TGN38/41 (Fig. 7D), this is in contrast to the situation 
in cells overexpressing full-length TGN38/41 (Fig. 4D). 
Similar results were obtained with COS cells transfected 
with the TGN38/41 A TAIL construct (data not shown). 
4. Discussion 
We have used an inducible xpression system in stably 
transfected cell lines to investigate he targeting and re- 
tention of TGN38/41. The ability to regulate xpression 
in stable transfectants affords a number of advantages 
over other systems: (i) a large population of cells express- 
ing similar amounts of protein can be easily monitored 
and are available for biochemical measurements, (ii) in 
the absence of an inducing agent there is very little 
TGN38/41 being produced and therefore any deleterious 
effects on the cells will be minimised (iii) expression can 
be induced to levels which cause mislocalisation of 
TGN38/41 but not detachment from the substrate as had 
been seen previously [3] and (iv) mislocalisation due to 
overexpression can be dissected from mislocalisation due 
to alterations in amino acid sequence. 
Expression of TGN41 in COS cells at high levels re- 
suited in its appearance in vesicles of various sizes scat- 
tered throughout the cytoplasm and in a greatly extended 
TGN. In some cells it was completely absent from its 
normally perinuclear localisation and only present in the 
vesicular structures. Interestingly, in cells overexpressing 
TGN41, where TGN41 is present in a diverse array of 
structures, 7-adaptin is also present on the majority of 
those structures. This might imply that overexpression f 
TGN41 leads to an expansion of the TGN and hence 
expansion of the membrane area coated with 7-adaptin. 
However, many of the TGN41-containing structures ob- 
served in transfectants overexpressing TGN41 corre- 
spond to early endosomes (as ascertained by the colocal- 
isation between internalised FITC-transferrin and 
TGN41; Fig. 5A,B). TGN38/41 has previously been 
shown to recycle between the c ll surface and the TGN 
[5,6], with a steady state distribution whereby the major- 
ity of the protein is in the TGN. These data suggest that 
overexpression f TGN41 disturbs the equillibrium of 
this steady state distribution such that accumulation oc- 
curs along the endocytic pathway rather than in the 
TGN. The fact that 7-adaptin is apparently associated 
with these ndocytic structures (Fig. 4C,D) implies some 
direct or indirect interaction between TGN41 and 7- 
adaptin, and the fact that overexpression f A TAIL 
TGN38/41 fails to lead to mislocalisation of 7-adaptin 
implicates the cytoplasmic domain of TGN38/41 in any 
such interaction. This is of note given the data which 
argue that TGN38/41 is required for vesicle formation 
from the TGN [26]. 
The mislocalisation of TGN38 upon overexpression 
has been observed previously; when a Tac-TGN38 
chimaera was overexpressed in MOP-8 cells [7]. The en- 
dogenous TGN38 was seen to disappear and it was pro- 
posed that there may either be competition for a satura- 
ble localisation mechanism or that there is a complete 
disruption of the TGN. Overexpression of TGN38/41 
may indeed result in the saturation of the retention ma- 
chinery leading to its escape from the TGN; however, if 
TGN38/41 is important in vesicle formation from the 
TGN its overexpression may lead to excessive vesicle 
formation and hence loss of TGN structure. 
Deletion of the cytoplasmic domain of TGN38/41 re- 
sulted in its expression at the cell surface but it was also 
demonstrated that a proportion is also retained in the 
TGN. In previous tudies [3,8] carried out using tran- 
sient transfections, expression of the same deletion mu- 
tant resulted in the detection of only plasma membrane 
staining. The reason for the difference in these results is 
not clear, however, it could be due to the levels of expres- 
sion and/or transfection systems used. The levels of cell 
surface expression observed in immunofluorescence 
analysis in the earlier studies were high enough to have 
masked any intracellular concentration of fluorescence 
signal. The lower levels of recombinant protein expres- 
sion obtained in this study permitted the detection of 
intracellular staining patterns in immunofluorescence 
analysis even in the presence of cell surface protein ex- 
pression. There is precedence for different results being 
456 B. Reaves, G. BantinglFEBS Letters 351 (1994) 448-456 
obtained from transient and permanent transfection sys- 
tems since it has been proposed that two contradictory 
sets of  results regarding regions of  the protein responsi- 
ble for the targeting of  the glucose transporter GLUT4 
[27,28] were obtained due to one being a stable expres- 
sion system and the other a transient system [29]. 
The presence of residual TGN38/41 in the TGN sug- 
gests that in addition to the retrieval/targeting informa- 
tion inherent in the cytoplasmic domain, and in particu- 
lar in the residues urrounding tyrosine 333, there is also 
a retention mechanism functioning. The residual 
TGN38/41 present in the TGN,  was apparent even at the 
highest levels of  induction (Fig. 7). These data parallel 
those seen for many of  the Golgi enzymes in that, even 
at expression levels several hundred-fold higher than 
normal, the retention system could not be saturated (re- 
viewed in [30]). We have not determined whether it is the 
lumenal domain or transmembrane domain that is re- 
sponsible for this retention, however, precedence in 
terms of the Golgi enzymes would suggest it may be the 
transmembrane domain and work by others has recently 
demonstrated that this is the case [10]. 
The length of  the transmembrane domain has recently 
been put forward as a possible determining factor in 
retention/residence in the Golgi stacks or plasma mem- 
brane [31]. The average length of  the hydrophobic do- 
main in 17 type II plasma membrane proteins was 20 
amino acids versus 15 for Golgi enzymes. Analysis of  the 
composit ion of  amino acids in this domain also revealed 
a preference for phenylalanine in the Golgi enzymes. 
This is consistent with the finding that polar residues are 
required on one face of  a predicted s-helix in the trans- 
membrane domain of  El glycoprotein of  avian coro- 
navirus for its retention in the Golgi [32]. The transmem- 
brane domain of  TGN38/41 is 21 amino acids in length 
but contains two phenylalanine r sidues. This may be 
consistent with its role in recycling between the TGN and 
the plasma membrane, needing the length to allow incor- 
poration upon arrival at the cell surface but also requir- 
ing some of  the properties of  the Golgi enzymes which 
would enable residence in the 'more disordered' environ- 
ment of  the lipid bilayer of  the TGN.  
The regulated expression system we have described 
and characterised will permit a detailed analysis, at phys- 
iologically relevant levels of  expression, of  sequence/ 
structural motifs involved in TGN to plasma membrane 
recycling pathways. 
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